XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus...
182 insider purchases on record · latest filing 2008-06-19.
Insiders have also filed 8 sale transactions at XTLB.